1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Lilly Back In The BACE Space Following Deal With AstraZeneca

 
• By Jessica Merrill

Eli Lilly has signed on as a risk-sharing partner with AstraZeneca to develop a BACE inhibitor for Alzheimer’s disease. The deal gives Lilly a mid-stage asset in the challenging field after two of its own candidates failed in late-stage trials.

With two recent clinical-stage failures in Alzheimer’s disease, Eli Lilly & Co. is turning to a risk-sharing collaboration with AstraZeneca PLC to develop and commercialize AstraZeneca’s oral beta secretase cleaving enzyme (BACE) inhibitor AZD3293 for the treatment of Alzheimer’s disease.

The companies announced the deal Sept. 16, which puts Lilly back in the mid-stage BACE inhibitor development game.

More from Clinical Trials

More from R&D